U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H26N4O3
Molecular Weight 382.4561
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VAPENDAVIR

SMILES

CCOC1=NOC2=CC(OCCC3CCN(CC3)C4=NN=C(C)C=C4)=CC=C12

InChI

InChIKey=DKSVBVKHUICELN-UHFFFAOYSA-N
InChI=1S/C21H26N4O3/c1-3-26-21-18-6-5-17(14-19(18)28-24-21)27-13-10-16-8-11-25(12-9-16)20-7-4-15(2)22-23-20/h4-7,14,16H,3,8-13H2,1-2H3

HIDE SMILES / InChI
Vapendavir (BTA-798) is an orally active capsid-binding inhibitor. It is a potent, orally bioavailable, broad spectrum inhibitor of the large group of HRVs. Vapendavir binds tightly to VP1s canyon and disrupts the ability of the capsid to bind to a specific cell surface receptor. This further inhibits the release of the viral RNA into the cell cytoplasm during the viral uncoating process (removing the lipid bilayer), thereby disrupting viral replication. Vapendavir is designed to be dosed orally. Vapendavir is in phase II clinical trials for the treatment of rhinovirus-induced aggravation of pre-existing asthma or COPD. Vapendavir has shown significant results in proof-of-concept studies. Thus far, from the Phase 1/2 studies conducted, vapendavir has demonstrated a desirable clinical pharmacology profile with high bioavailability, linear pharmacokinetic profile, remained unaffected by concomitant medications, and was not exclusively metabolized.

Approval Year

PubMed

PubMed

TitleDatePubMed
The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication.
2014 Nov
Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68.
2015 Dec
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: 300-patient, multicenter, randomized, double-blind, placebo-controlled study of vapendavir in adults with mild to moderate asthma who also had symptoms of HRV infection. The purpose of the study was to evaluate the safety, tolerability and effectiveness of vapendavir in reducing the duration and symptoms of common cold, asthma, and lowering the risk of asthma exacerbation. Roughly 1200 individuals were screened in order to randomize 300 subjects, 155 in the vapendavir arm and 145 in the placebo group.Vapendavir was given two times daily for six consecutive days. Subjects who received 264 mg of vapendavir showed significant reduction in mean viral load. http://s1.q4cdn.com/460208960/files/Feb-8-2016_BOTA_Dushyanth.pdf
Rhinovirus, Upper Respiratory Tract Infection: Vapendavir Tablets, 264 mg, twice daily
Route of Administration: Oral
Vapendavir inhibited EV71 replication of all isolates (average EC50s of 0.7uM)
Name Type Language
VAPENDAVIR
INN  
INN  
Official Name English
3-ETHOXY-6-(2-(1-(6-METHYLPYRIDAZIN-3-YL)PIPERIDIN-4-YL)ETHOXY)-1,2-BENZOXAZOLE
Systematic Name English
BTA798
Code English
BTA-798
Code English
vapendavir [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C281
Created by admin on Sat Dec 16 17:10:31 GMT 2023 , Edited by admin on Sat Dec 16 17:10:31 GMT 2023
Code System Code Type Description
SMS_ID
300000034464
Created by admin on Sat Dec 16 17:10:31 GMT 2023 , Edited by admin on Sat Dec 16 17:10:31 GMT 2023
PRIMARY
INN
9501
Created by admin on Sat Dec 16 17:10:31 GMT 2023 , Edited by admin on Sat Dec 16 17:10:31 GMT 2023
PRIMARY
NCI_THESAURUS
C152831
Created by admin on Sat Dec 16 17:10:31 GMT 2023 , Edited by admin on Sat Dec 16 17:10:31 GMT 2023
PRIMARY
CAS
439085-51-5
Created by admin on Sat Dec 16 17:10:31 GMT 2023 , Edited by admin on Sat Dec 16 17:10:31 GMT 2023
PRIMARY
EPA CompTox
DTXSID40195984
Created by admin on Sat Dec 16 17:10:31 GMT 2023 , Edited by admin on Sat Dec 16 17:10:31 GMT 2023
PRIMARY
FDA UNII
Q8LVL5Z68H
Created by admin on Sat Dec 16 17:10:31 GMT 2023 , Edited by admin on Sat Dec 16 17:10:31 GMT 2023
PRIMARY
DRUG BANK
DB05181
Created by admin on Sat Dec 16 17:10:31 GMT 2023 , Edited by admin on Sat Dec 16 17:10:31 GMT 2023
PRIMARY
PUBCHEM
504457
Created by admin on Sat Dec 16 17:10:31 GMT 2023 , Edited by admin on Sat Dec 16 17:10:31 GMT 2023
PRIMARY